Get Permission

In the November 15 issue of The ASCO Post, the article, “Strong Showing for Ado-Trastuzumab Emtansine in Advanced HER2-Positive Heavily Pretreated Breast Cancer,” contained the following errors in the reported outcomes data for the TH3RESA trial:

  • The article incorrectly stated the median survival in the control arm at the first interim analysis; this finding was actually 14.9 months.
  • The any-grade adverse event rates included in the article were incorrect. These should be 94% for those who received ado-trastuzumab emtansine (Kadcyla) vs 89% for the control arm.

The ASCO Post regrets the errors. A corrected version of the article appears at ■




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.